We Can Medicines Co Ltd

We Can Medicines Co Ltd has a debt-to-equity ratio of 1.23, indicating a moderate reliance on debt financing, and a current ratio of 1.54, suggesting it has sufficient short-term assets to cover its liabilities. The company's liquidity position is assessed as medium, with a negative net cash position after subtracting total debt, which may limit its flexibility in capital deployment.

The company's profitability is modest, with a return on equity of 0.93% and a return on assets of 0.33%, both below the typical thresholds for strong performance in the drug retailing industry. These metrics suggest that the company is generating limited returns relative to its equity and asset base, which could be a concern for investors seeking higher returns.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, indicating a high level of exposure to local market conditions and regulatory changes. This lack of diversification could increase the company's vulnerability to regional economic downturns or policy shifts.

The company's growth trajectory is not clearly defined, as there are no disclosed revenue growth rates or future projections in the available data. The absence of forward-looking guidance makes it difficult to assess the company's long-term growth potential or its ability to expand its market share.

The company's risk profile includes a medium liquidity risk and a low dilution risk, with no immediate signs of equity dilution through new share issuance or convertible instruments. However, the negative net cash position after debt suggests that the company may need to raise additional capital in the future, which could introduce new risks.

There are no recent events or filings disclosed in the available data that would indicate significant changes in the company's operations, strategy, or financial position. The lack of recent disclosures may suggest a stable but uneventful business environment for the company.

Cash conversion of 4.14 significantly exceeds the Drug Retailers cohort median of 1.51, indicating superior operational efficiency.

Net margin of 1.32% matches the cohort median, demonstrating competitive profitability relative to peers in the drug retail sector.

Free cash flow grew 7.4% year-over-year to TWD 211.6 million, showing improved cash generation despite recent net losses.

Revenue remained stable at TWD 3.22 billion in FY0, suggesting resilient top-line performance amidst fluctuating profitability metrics.

Dilution risk is assessed as low, providing reassurance to shareholders regarding potential equity value erosion from new issuances.

Credit risk is flagged as high, signaling significant potential for financial distress or inability to meet debt obligations.

Debt-to-equity ratio of 1.23 vastly exceeds the cohort median of 0.38, highlighting excessive leverage compared to peers.

Operating margin of 1.45% falls below the cohort median of 2.42%, suggesting weaker core operational profitability than competitors.

Revenue TWD 814.6M; Operating income -TWD 35.6M.

• ▍Revenue TWD 814.6M
• ▍Operating income -TWD 35.6M
• ▍Net margin -4.1%

Revenue TWD 812.6M; Operating income -TWD 23.1M.

• ▍Revenue TWD 812.6M
• ▍Operating income -TWD 23.1M
• ▍Net margin -2.6%

Revenue TWD 823.9M; Operating income -TWD 7.0M.

• ▍Revenue TWD 823.9M
• ▍Operating income -TWD 7.0M
• ▍Net margin -0.4%

Revenue TWD 3.27B, +4,7% YoY; Operating income −345,7% YoY.

• ▍Revenue TWD 3.27B, +4,7% YoY
• ▍Operating income −345,7% YoY
• ▍Net income −418,7% YoY
• ▍Free cash flow −8,3% YoY
• ▍Net margin -1.4%